Journal article icon

Journal article

Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity.

Abstract:

RAD51 is a key protein in the homologous recombination (HR) pathway of DNA double-strand break repair, and HR represents a novel target for cancer therapy. Because imatinib (Gleevec) has been reported to reduce RAD51 protein levels, we tested the clonogenic survival for RT112, H1299, PANC1, and PC3 tumor cell lines of varying p53 status and normal GM05757 normal fibroblasts after exposure to single agent imatinib (0-20 micromol/L; 0-72 hours). We also combined imatinib with DNA damaging agent...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


Expand authors...
Journal:
Molecular cancer therapeutics
Volume:
8
Issue:
1
Pages:
203-213
Publication date:
2009-01-05
DOI:
EISSN:
1538-8514
ISSN:
1535-7163
URN:
uuid:7b98824a-7b33-4f6e-9f27-6d272a08cddc
Source identifiers:
131100
Local pid:
pubs:131100

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP